MassMutual Private Wealth & Trust’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-288
| Closed | -$9.05K | – | 2379 |
|
|
2026
Q2 | $9.05K | Hold |
288
| – | – | ﹤0.01% | 1446 |
|
|
2026
Q1 | $7.13K | Buy |
288
+43
| +18% | +$1.02K | ﹤0.01% | 1520 |
|
|
2025
Q4 | $5.72K | Hold |
245
| – | – | ﹤0.01% | 1628 |
|
|
2025
Q3 | $4.83K | Sell |
245
-5
| -2% | -$103 | ﹤0.01% | 1686 |
|
|
2025
Q2 | $5.42K | Sell |
250
-14
| -5% | -$330 | ﹤0.01% | 1609 |
|
|
2025
Q1 | $6.4K | Buy |
264
+19
| +8% | +$428 | ﹤0.01% | 1484 |
|
|
2024
Q4 | $5.11K | Hold |
245
| – | – | ﹤0.01% | 1527 |
|
|
2024
Q3 | $4.87K | Hold |
245
| – | – | ﹤0.01% | 1395 |
|
|
2024
Q2 | $3.8K | Hold |
245
| – | – | ﹤0.01% | 1409 |
|
|
2024
Q1 | $3.9K | Hold |
245
| – | – | ﹤0.01% | 1349 |
|
|
2023
Q4 | $4.12K | Buy |
245
+67
| +38% | +$916 | ﹤0.01% | 1289 |
|
|
2023
Q3 | $2.08K | Hold |
178
| – | – | ﹤0.01% | 1493 |
|
|
2023
Q2 | $2.39K | Sell |
178
-94
| -35% | -$1.35K | ﹤0.01% | 1424 |
|
|
2023
Q1 | $4.51K | Hold |
272
| – | – | ﹤0.01% | 1176 |
|
|
2022
Q4 | $5K | Buy |
272
+63
| +30% | +$970 | ﹤0.01% | 976 |
|
|
2022
Q3 | $3K | Buy |
+209
| New | +$2.48K | ﹤0.01% | 1072 |
|
|
2022
Q1 | – | Sell |
-85
| Closed | -$1K | – | 1532 |
|
|
2021
Q4 | $1K | Buy |
+85
| New | +$559 | ﹤0.01% | 1194 |
|
Other funds holding CPRX
MassMutual Private Wealth & Trust's CPRX Position: Q3 2026 in Review
MassMutual Private Wealth & Trust sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 288 shares — an estimated $9.05K sold.
MassMutual Private Wealth & Trust first reported a position in CPRX in Q4 2021 and held it in 17 quarters. The position peaked at $9.05K in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- MassMutual Private Wealth & Trust reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- MassMutual Private Wealth & Trust sold 288 Catalyst Pharmaceutical shares in Q3 2026, an estimated $9.05K.
- MassMutual Private Wealth & Trust first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 17 quarters.
- MassMutual Private Wealth & Trust's Catalyst Pharmaceutical position peaked at $9.05K in Q2 2026.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.